The Prognostic Value of Altered eIF3a and Its Association with p27 in Non-Small Cell Lung Cancers
Open Access
- 30 April 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (4) , e96008
Abstract
Over-expressed eukaryotic initiation factor 3a (eIF3a) in non-small cell lung cancer (NSCLC) contributed to cisplatin sensitivity. However, the role of eIF3a in oncogenesis was still controversial. This study was designed to investigate the prognostic impact of eIF3a and p27 in radically resected NSCLC patients. The expression levels of subcellular eIF3a and p27 were evaluated immunohistochemically in 537 radically resected NSCLC samples, and another cohort of 210 stage II NSCLC patients. Disease specific survival (DSS) and disease free survival (DFS) were analyzed by Kaplan-Meier method and Cox regression model. The subcellular expression of eIF3a was strongly correlated with status of p27 (Spearman rank coefficient correlation for cytoplasmic eIF3a and p27 = 0.653, for nuclear staining = 0.716). Moreover, survival analysis revealed favorable prognostic impact of nuclear eIF3a, p27, and the combination high nuclear staining on NSCLC (Hazards Ratio = 0.360, 95%CI = 0.109–0.782, P = 0.028). In addition, interaction research between biomarkers and chemotherapy status disclosed cisplatin-based regimen trend to prolong DSS of stage II NSCLC patients with high eIF3a-C (P = 0.036)and low p27-N (P = 0.031). Our findings suggested altered eIF3a expression closely correlated with p27 status, and the association was of prognostic value for resected NSCLC. Altered expression of eIF3a and p27 predicted prognosis of NSCLC independently.Keywords
This publication has 26 references indexed in Scilit:
- Synthesis, Pharmacophores, and Mechanism Study of Pyridin‐2(1H)‐one Derivatives as Regulators of Translation Initiation Factor 3AArchiv der Pharmazie, 2013
- The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patientsLung Cancer, 2013
- Overexpression of eIF3a in Squamous Cell Carcinoma of the Oral Cavity and Its Putative Relation to Chemotherapy ResponseJournal of Oncology, 2012
- Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinomaOncogene, 2011
- p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted TherapiesClinical Cancer Research, 2011
- The function of p27KIP1during tumor developmentExperimental & Molecular Medicine, 2009
- Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic ProgramJournal of Clinical Oncology, 2007
- p150 Overexpression in gastric carcinoma: The association with p53, apoptosis and cell proliferationInternational Journal of Cancer, 2004
- Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growthOncogene, 2004
- Are p27 and p21 Cytoplasmic Oncoproteins?Cell Cycle, 2002